A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 weight-loss drugs, Zepbound and Mounjaro, missed estimates for the second ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Health-care companies rose after strong earnings from one obesity-drug maker. Eli Lilly shares rose after it reiterated its forecast for 32% 2025 revenue growth, amid rising demand for its Zepbound ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.